Combined Tretinoin and Tranexamic Acid Cream for Hyperpigmentation After Electrosurgery
Effectiveness Of Combined Tretinoin and Tranexamic Acid Cream Compred With Tretinoin Cream Alone for Past-Electrosurgical Hyperpigmentation in Patients With Benign Skin Tumors.
This study aims to evaluate the effectiveness of a cream containing tretinoin and tranexamic acid compared with tretinoin cream alone in managing post-inflammatory hyperpigmentation following electrosurgery in patients with benign skin tumors. Post-inflammatory hyperpigmentation is a condition in which the skin becomes darker after inflammation or injury, including after certain dermatological procedures. This discoloration may affect patients' appearance and quality of life.
The study will compare two treatment groups: one receiving a combination of tretinoin and tranexamic acid cream and the other receiving tretinoin cream alone. Participants will undergo treatment for four weeks. The researchers will evaluate changes in skin pigmentation and skin barrier function using the Post-Inflammatory Hyperpigmentation Area and Severity Index (PIHASI), transepidermal water loss (TEWL), and skin hydration measurements.
The findings are expected to provide information about the potential benefits of combining tretinoin and tranexamic acid for managing hyperpigmentation after electrosurgery.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Wahyu Lestari, MD, PhD, Sp.DVE
- Phone Number: +628126991901
- Email: wahyu_lestari2000@usk.ac.id
Study Contact Backup
- Name: Sarah Nabila
- Phone Number: +6285270340806
- Email: sarahnabila806@gmail.com
Study Locations
-
-
Special Region of Aceh
-
Banda Aceh, Special Region of Aceh, Indonesia, 24415
- Recruiting
- Dr. Zainoel Abidin Regional General Hospital
-
Contact:
- Wahyu Lestari, MD, PhD, Sp.DVE
- Phone Number: +628126991901
- Email: wahyu_lestari2000@usk.ac.id
-
Contact:
- Sarah Nabila
- Phone Number: +6285270340806
- Email: sarahnabila806@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adults aged 18 to 60 years.
- Patients diagnosed with benign skin tumors.
- Patients undergoing electrosurgical treatment.
- Patients willing to participate in the study from enrollment through completion and provide informed consent.
Exclusion Criteria:
- Pregnant women.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Experimental: Tretinoin and Tranexamic Acid Cream
Participants assigned to this group will receive a topical cream containing tretinoin and tranexamic acid following electrosurgery. The intervention will be administered according to the study protocol to evaluate changes in post-electrosurgical hyperpigmentation. |
A topical cream containing a combination of tretinoin and tranexamic acid will be administered to the designated treatment area following electrosurgery. The intervention is being investigated to evaluate its potential effect on post-electrosurgical hyperpigmentation. Changes in skin pigmentation will be assessed according to the study protocol to determine the observed response to treatment. |
|
Active Comparator: Active Comparator: Tretinoin Cream
Participants assigned to this group will receive topical tretinoin cream following electrosurgery. This group will serve as a comparator to assess differences in post-electrosurgical hyperpigmentation between the two treatment groups. |
Topical tretinoin cream will be administered to the designated treatment area following electrosurgery. This intervention will serve as the comparator for evaluating differences in post-electrosurgical hyperpigmentation between the treatment groups. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Post-Inflammatory Hyperpigmentation Area and Severity Index (PIHASI) Score
Time Frame: Baseline and Week 4
|
Changes in post-inflammatory hyperpigmentation will be assessed using the PIHASI score. Scores will be recorded before treatment and at the scheduled follow-up assessment to evaluate changes in pigmentation severity following the application of the study creams. |
Baseline and Week 4
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Transepidermal Water Loss (TEWL)
Time Frame: Baseline and Week 4
|
Transepidermal water loss will be measured to assess changes in skin barrier function from baseline to Week 4. |
Baseline and Week 4
|
|
Change in Skin Hydration
Time Frame: Baseline and Week 4
|
Skin hydration will be measured to assess changes in skin moisture levels from baseline to Week 4. |
Baseline and Week 4
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Wahyu Lestari, MD, PhD, Sp.DVE, RSUD dr. Zainoel Abidin
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Wounds and Injuries
- Skin Diseases
- Pigmentation Disorders
- Body Temperature Changes
- Heat Stress Disorders
- Pathological Conditions, Signs and Symptoms
- Skin and Connective Tissue Diseases
- Signs and Symptoms
- Hyperthermia
- Hyperpigmentation
- Organic Chemicals
- Retinoids
- Carotenoids
- Polyenes
- Alkenes
- Hydrocarbons, Acyclic
- Hydrocarbons
- Cyclohexenes
- Cyclohexanes
- Cycloparaffins
- Hydrocarbons, Alicyclic
- Hydrocarbons, Cyclic
- Terpenes
- Pigments, Biological
- Biological Factors
- Diterpenes
- Vitamin A
- Tretinoin
Other Study ID Numbers
Other Study ID Numbers
- 124/ETIK-RSUDZA/2026
- 124/ETIK-RSUDZA/2026 (Other Identifier: Komite Etik Penelitian Kesehatan RSUD dr. Zainoel Abidin)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.